BioLineRx Ltd. (BLRX)

Market Cap	24.21M
Revenue (ttm)	22.34M
Net Income (ttm)	-3.40M
Shares Out	2.23B
EPS (ttm)	-0.00
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	258,338
Open	5.54
Previous Close	5.82
Day's Range	5.30 - 5.94
52-Week Range	2.30 - 35.60
Beta	0.90
Analysts	Strong Buy
Price Target	19.00 (+249.27%)
Earnings Date	May 27, 2025

About BLRX

BioLineRx Ltd., a commercial stage biopharmaceutical company, develops and commercializes therapeutics for oncology and rare diseases. The company’s pipeline includes APHEXDA (motixafortide), a peptide that is in Phase 1 clinical trial for the treatment of sickle cell disease, and Phase 2b clinical trial for the treatment of pancreatic cancer, as well as completed Phase 3 clinical trial for the treatment of multiple myeloma. It develops BL-5010, a pen-like applicator containing an acidic aqueous solution for the non-surgical removal of skin les...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Jul 25, 2011
• Employees: 28
• Stock Exchange: NASDAQ
• Ticker Symbol: BLRX
• Website: https://www.biolinerx.com

Financial Performance

In 2024, BioLineRx's revenue was $28.94 million, an increase of 502.92% compared to the previous year's $4.80 million. Losses were -$9.22 million, -84.79% less than in 2023.

Analyst Forecast

According to 2 analysts, the average rating for BLRX stock is "Strong Buy." The 12-month stock price forecast is $19.0, which is an increase of 249.27% from the latest price.

Price Target

$19.0

(249.27% upside)

Analyst Consensus: Strong Buy